Strategies for rapidly mapping proviral integration sites and assessing cardiogenic potential of nascent human induced pluripotent stem cell clones

Experimental Cell Research

Volumn 327, Issue 2, 2014, Pages 297-306

  Dambrot, Cheryl ^a   Buermans, Henk P J ^a   Varga, Eszter ^b,c   Kosmidis, Georgios ^a   Langenberg, Karin ^d   Casini, Simona ^a   Elliott, David A ^e   Dinnyes, Andras ^b,c   Atsma, Douwe E ^a   Mummery, Christine L ^a,f   Braam, Stefan R ^d   Davis, Richard P ^a,f  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BIOTALENTUM LTD   (Hungary)

^c SZENT ISTVÁN UNIVERSITY   (Hungary)

^d Pluriomics BV   (Germany)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

^f Netherlands Proteomics Institute   (Netherlands)

Author keywords

Cardiomyocytes; Cell differentiation; High throughput DNA sequencing; Human induced pluripotent stem cell

Indexed keywords

ACTIVIN A; ALPHA ACTININ 1; BONE MORPHOGENETIC PROTEIN 4; KRUPPEL LIKE FACTOR 4; MYC PROTEIN; MYOSIN HEAVY CHAIN BETA; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NKX2.5; TRANSCRIPTION FACTOR SOX2; TROPOMYOSIN; TROPONIN I;

ARTICLE; CELL CLONE; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE MAPPING; HEART DEVELOPMENT; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; SKIN FIBROBLAST; TOOTH PULP; TRANSPOSON; VIRUS DNA CELL DNA INTERACTION; CARDIOMYOCYTES; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; DERMIS; FIBROBLAST; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HIGH THROUGHPUT SCREENING; HIGH-THROUGHPUT DNA SEQUENCING; HUMAN INDUCED PLURIPOTENT STEM CELL; METABOLISM; NUCLEAR REPROGRAMMING; PROVIRUS; SOUTHERN BLOTTING;

CARDIOMYOCYTES; CELL DIFFERENTIATION; HIGH-THROUGHPUT DNA SEQUENCING; HUMAN INDUCED PLURIPOTENT STEM CELL;

BLOTTING, SOUTHERN; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DENTAL PULP; DERMIS; FIBROBLASTS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MYOCYTES, CARDIAC; NUCLEAR REPROGRAMMING; PROVIRUSES; VIRUS INTEGRATION;

EID: 84907688545     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.05.001     Document Type: Article

References (45)

1. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
2. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., Nie J., Jonsdottir G.A., Ruotti V., Stewart R., Slukvin I.I., Thomson J.A. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
3. Cahan P., Daley G.Q. Origins and implications of pluripotent stem cell variability and heterogeneity. Nat. Rev. Mol. Cell Biol. 2013, 14:357-368.
4. Park I.H., Daley G.Q. Human iPS cell derivation/reprogramming. Curr. Protoc. Stem Cell Biol. 2009, 8. (4A.1.1-4A.1.8).
5. Papapetrou E.P., Sadelain M. Generation of transgene-free human induced pluripotent stem cells with an excisable single polycistronic vector. Nat. Protoc. 2011, 6:1251-1273.
6. Hu B.Y., Weick J.P., Yu J., Ma L.X., Zhang X.Q., Thomson J.A., Zhang S.C. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc. Nat. Acad. Sci. U.S.A. 2010, 107:4335-4340.
7. Boulting G.L., Kiskinis E., Croft G.F., Amoroso M.W., Oakley D.H., Wainger B.J., Williams D.J., Kahler D.J., Yamaki M., Davidow L., Rodolfa C.T., Dimos J.T., Mikkilineni S., MacDermott A.B., Woolf C.J., Henderson C.E., Wichterle H., Eggan K. A functionally characterized test set of human induced pluripotent stem cells. Nat. Biotechnol. 2011, 29:279-286.
8. Devine M.J., Ryten M., Vodicka P., Thomson A.J., Burdon T., Houlden H., Cavaleri F., Nagano M., Drummond N.J., Taanman J.W., Schapira A.H., Gwinn K., Hardy J., Lewis P.A., Kunath T. Parkinson's disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. Nat. Commun. 2011, 2:440.
9. Thatava T., Kudva Y.C., Edukulla R., Squillace K., De Lamo J.G., Khan Y.K., Sakuma T., Ohmine S., Terzic A., Ikeda Y. Intrapatient variations in type 1 diabetes-specific iPS cell differentiation into insulin-producing cells. Mol. Ther. 2013, 21:228-239.
10. Hawley R.G. Does retroviral insertional mutagenesis play a role in the generation of induced pluripotent stem cells?. Mol. Ther. 2008, 16:1354-1355.
11. Carlos Polanco J., Ho M.S., Wang B., Zhou Q., Wolvetang E., Mason E., Wells C.A., Kolle G., Grimmond S.M., Bertoncello I., O'Brien C., Laslett A.L. Identification of unsafe human induced pluripotent stem cell lines using a robust surrogate assay for pluripotency. Stem Cells 2013, 31:1498-1510.
12. Winkler T., Cantilena A., Metais J.Y., Xu X., Nguyen A.D., Borate B., Antosiewicz-Bourget J.E., Wolfsberg T.G., Thomson J.A., Dunbar C.E. No evidence for clonal selection due to lentiviral integration sites in human induced pluripotent stem cells. Stem Cells 2010, 28:687-694.
13. Zheng W., Wang Y., Chang T., Huang H., Yee J.K. Significant differences in genotoxicity induced by retrovirus integration in human T cells and induced pluripotent stem cells. Gene 2013, 519:142-149.
14. Wu C., Dunbar C.E. Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity. Front. Med. 2011, 5:356-371.
15. Dambrot C., van de Pas S., van Z.L., Brandl B., Wang J.W., Schalij M.J., Hoeben R.C., Atsma D.E., Mikkers H.M., Mummery C.L., Freund C. Polycistronic lentivirus induced pluripotent stem cells from skin biopsies after long term storage, blood outgrowth endothelial cells and cells from milk teeth. Differentiation 2013, 85:101-109.
16. Ng E.S., Davis R., Stanley E.G., Elefanty A.G. A protocol describing the use of a recombinant protein-based, animal product-free medium (APEL) for human embryonic stem cell differentiation as spin embryoid bodies. Nat. Protoc. 2008, 3:768-776.
17. Davis R.P., Nemes C., Varga E., Freund C., Kosmidis G., Gkatzis K., de J.D., Szuhai K., Dinnyes A., Mummery C.L. Generation of induced pluripotent stem cells from human foetal fibroblasts using the sleeping beauty transposon gene delivery system. Differentiation 2013, 86:30-37.
18. Uren A.G., Mikkers H., Kool J., van der Weyden L., Lund A.H., Wilson C.H., Rance R., Jonkers J., van L.M., Berns A., Adams D.J. A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites. Nat. Protoc. 2009, 4:789-798.
19. Yin B. Isolation of genomic insertion sites of proviruses using Splinkerette-PCR-based procedures. Methods Mol. Biol. 2011, 687:25-42.
20. Koudijs M.J.M., Klijn C., Weyden L.V.D., Kool J., Hoeve J., Sie D., Prasetyanti P.R., Schut E., Kas S., Whipp T., Cuppen E., Wessels L., Adams D.J. High-throughput semiquantitative analysis of insertional mutations in heterogeneous tumors. Genome 2011, 2181-2189.
21. Quinlan A.R., Hall I.M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 2010, 26:841-842.
22. Davis R.P., Casini S., van den Berg C.W., Hoekstra M., Remme C.A., Dambrot C., Salvatori D., Oostwaard D.W., Wilde A.A., Bezzina C.R., Verkerk A.O., Freund C., Mummery C.L. Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation 2012, 125:3079-3091.
23. Bellin M., Casini S., Davis R.P., D'Aniello C., Haas J., Ward-van Oostwaard D., Tertoolen L.G., Jung C.B., Elliott D.A., Welling A., Laugwitz K.L., Moretti A., Mummery C.L. Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. EMBO J. 2013, 32:3161-3175.
24. Lan F., Lee A.-S., Liang P., Sanchez-Freire V., Nguyen P.-K., Wang L., Han L., Yen M., Wang Y., Sun N., Abilez O.-J., Hu S., Ebert A.-D., Navarrete E.-G., Simmons C.-S., Wheeler M., Pruitt B., Lewis R., Yamaguchi Y., Ashley E.-A., Bers D.-M., Robbins R.-C., Longaker M.-T., Wu J.-C. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 2013, 12:101-113.
25. Yusa K., Rad R., Takeda J., Bradley A. Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. Nat. Methods 2009, 6:363-369.
26. Paige S.L., Osugi T., Afanasiev O.K., Pabon L., Reinecke H., Murry C.E. Endogenous Wnt/beta-catenin signaling is required for cardiac differentiation in human embryonic stem cells. PLoS One 2010, 5:e11134.
27. Elliott D.A., Braam S.R., Koutsis K., Ng E.S., Jenny R., Lagerqvist E.L., Biben C., Hatzistavrou T., Hirst C.E., Yu Q.C., Skelton R.J., Ward-van O.D., Lim S.M., Khammy O., Li X., Hawes S.M., Davis R.P., Goulburn A.L., Passier R., Prall O.W., Haynes J.M., Pouton C.W., Kaye D.M., Mummery C.L., Elefanty A.G., Stanley E.G. NKX2-5(eGFP/w) hESCs for isolation of human cardiac progenitors and cardiomyocytes. Nat. Methods 2011, 8:1037-1040.
28. Willems E., Spiering S., Davidovics H., Lanier M., Xia Z., Dawson M., Cashman J., Mercola M. Small-molecule inhibitors of the Wnt pathway potently promote cardiomyocytes from human embryonic stem cell-derived mesoderm. Circ. Res. 2011, 109:360-364.
29. Wang H., Hao J., Hong C.C. Cardiac induction of embryonic stem cells by a small molecule inhibitor of Wnt/beta-catenin signaling. ACS Chem. Biol. 2011, 6:192-197.
30. He J.Q., Ma Y., Lee Y., Thomson J.A., Kamp T.J. Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circ. Res. 2003, 93:32-39.
31. Jonsson M.K., van Veen T.A., Goumans M.J., Vos M.A., Duker G., Sartipy P. Improvement of cardiac efficacy and safety models in drug discovery by the use of stem cell-derived cardiomyocytes. Expert Opin. Drug Discovery 2009, 4:357-372.
32. Itzhaki I., Rapoport S., Huber I., Mizrahi I., Zwi-Dantsis L., Arbel G., Schiller J., Gepstein L. Calcium handling in human induced pluripotent stem cell derived cardiomyocytes. PLoS One 2011, 6. (e18037-e18037).
33. Burridge P.W., Thompson S., Millrod M.A., Weinberg S., Yuan X., Peters A., Mahairaki V., Koliatsos V.E., Tung L., Zambidis E.T. A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability. PLoS One 2011, 6:e18293.
34. Zhang J., Wilson G.F., Soerens A.G., Koonce C.H., Yu J., Palecek S.P., Thomson J.A., Kamp T.J. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ. Res. 2009, 104:e30-e41.
35. Zhang J., Klos M., Wilson G.F., Herman A.M., Lian X., Raval K.K., Barron M.R., Hou L., Soerens A.G., Yu J., Palecek S.P., Lyons G.E., Thomson J.A., Herron T.J., Jalife J., Kamp T.J. Extracellular matrix promotes highly efficient cardiac differentiation of human pluripotent stem cells: the matrix sandwich method. Circ. Res. 2012, 111:1125-1136.
36. Lian X., Zhang J., Azarin S.M., Zhu K., Hazeltine L.B., Bao X., Hsiao C., Kamp T.J., Palecek S.P. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/beta-catenin signaling under fully defined conditions. Nat. Protoc. 2013, 8:162-175.
37. Costa M., Sourris K., Hatzistavrou T., Elefanty A.G., Stanley E.G. Expansion of human embryonic stem cells in vitro. Curr. Protoc. Stem Cell Biol. 2008, 5. (1C.1.1-1C.1.7).
38. Mummery C.L., Zhang J., Ng E.S., Elliott D.A., Elefanty A.G., Kamp T.J. Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ. Res. 2012, 111:344-358.
39. Kattman S.J., Witty A.D., Gagliardi M., Dubois N.C., Niapour M., Hotta A., Ellis J., Keller G. Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell 2011, 8:228-240.
40. Minami I., Yamada K., Otsuji T.G., Yamamoto T., Shen Y., Otsuka S., Kadota S., Morone N., Barve M., Asai Y., Tenkova-Heuser T., Heuser J.E., Uesugi M., Aiba K., Nakatsuji N. A small molecule that promotes cardiac differentiation of human pluripotent stem cells under defined, cytokine- and xeno-free conditions. Cell Rep. 2012, 2:1448-1460.
41. Kobayashi H., Yamada K., Morita S., Hiura H., Fukuda A., Kagami M., Ogata T., Hata K., Sotomaru Y., Kono T. Identification of the mouse paternally expressed imprinted gene Zdbf2 on chromosome 1 and its imprinted human homolog ZDBF2 on chromosome. Genomics 2009, 93:461-472.
42. Ieda M., Tsuchihashi T., Ivey K.N., Ross R.S., Hong T.T., Shaw R.M., Srivastava D. Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin signaling. Dev. Cell 2009, 16:233-244.
43. Dambrot C., Passier R., Atsma D., Mummery C.L. Cardiomyocyte differentiation of pluripotent stem cells and their use as cardiac disease models. Biochem. J. 2011, 434:25-35.
44. Davis R.P., van den Berg C.W., Casini S., Braam S.R., Mummery C.L. Pluripotent stem cell models of cardiac disease and their implication for drug discovery and development. Trends Mol. Med. 2011, 17:475-484.
45. Rajamohan D., Matsa E., Kalra S., Crutchley J., Patel A., George V., Denning C. Current status of drug screening and disease modelling in human pluripotent stem cells. Bioessays 2013, 35:281-298.